Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β-agonists (ICS/LABA) in patients with uncontrolled asthma: An open-label, randomized, controlled trial.

•Fluticasone furoate/vilanterol was effective in asthma uncontrolled on ICS.•Fluticasone furoate/vilanterol was non-inferior to usual ICS/LABA for control.•Usual ICS/LABA was fluticasone propionate/salmeterol or budesonide/formoterol.•Study was in a tightly controlled setting with adherence and correct use monitored.•Fluticasone furoate/vilanterol safety profile was in line with previous experience.